NCT04882462 - Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC. | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

December 31, 2022

Conditions

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

Nimotuzumab

Nimotuzumab, 400mg, intravenously every 3 weeks, for at least 18 weeks

DRUG

Sintilimab

Sintilimab, 200mg, intravenously every 3 weeks, for at least 18 weeks;

DRUG

Chemotherapy drug

Chemotherapy drugs were selected by the investigator, every 3 weeks, for 18 weeks